Ultragenyx Pharmaceutical (RARE) Payables (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Payables data on file, last reported at $42.0 million in Q1 2026.

• Quarterly Payables fell 11.49% year-over-year to $42.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.0 million (down 11.49% YoY) and the FY2025 annual result came in at $31.0 million, down 20.51% from the prior year.
• Payables rose to $42.0 million in Q1 2026 per RARE's latest filing, from $31.0 million in the prior quarter.
• Across five years, Payables topped out at $59.8 million in Q2 2024 and bottomed at $23.5 million in Q3 2022.
• The 5-year median for Payables is $40.6 million (2025), against an average of $39.5 million.
• The widest annual swing landed in 2022, when Payables soared 152.5%; it then slumped 42.75% in 2025.
• Tracing RARE's Payables over 5 years: stood at $43.3 million in 2022, then dropped by 2.68% to $42.1 million in 2023, then dropped by 7.39% to $39.0 million in 2024, then retreated by 20.51% to $31.0 million in 2025, then soared by 35.48% to $42.0 million in 2026.
• Per Business Quant, the three latest RARE Payables figures stand at $42.0 million (Q1 2026), $31.0 million (Q4 2025), and $40.6 million (Q3 2025).

Peer Comparison